A quick recap

In our previous blog post, we made the case that the wearable monitoring market has become a red ocean, that the next opportunity for medical device startups is in therapy-delivery wearables, and that the durable moat for those systems isn’t the sensor or the therapy mechanism alone — it’s the closed loop between therapy delivered and patient response captured.

This part is about how to actually build a closed loop system, highlighting five operating choices that consistently compress time and risk.

Five choices that can compress time and risk

Moving from therapy hypothesis to therapy-delivery wearable is a long road. The teams that make faster progress with lower risk tend to share a small set of operating habits. Five of them stand out.

1. Sequence the work to meet the next proof point

In a tighter capital environment, every funding round is expected to convert money into measurable risk reduction in order to justify the next round. Each major decision — what to design, what to defer, what to document, what to test — should serve a specific clinical, regulatory, or financing milestone, and not necessarily the eventual complete platform. New feature ideas will emerge constantly. Most belong on a future-version list and not in the iteration of the product for the next critical milestone.

For a wearable therapy device, the first milestone isn’t a fully integrated wearable platform. It’s often a proof-of-concept study showing that the therapy mechanism actually works. Once the efficacy of therapy has been demonstrated, the wearable system can be designed around making that therapy more usable, targeted, adaptive, and scalable.

• POC validates feasibility: The impact of therapy is real, the signals indicative of the need for therapy, and the effects of therapy exist.
• V1 generates defensible clinical evidence: The device performs reliably in target patients, with traceable data and documented controls.
• V2 optimizes for market scale: Cost, manufacturability, usability.

Designing for traceability from day one is part of this. Investors and regulators increasingly expect to see system architecture that can evolve without major rework, structured and traceable data, and a clear line from indications to claims to evidence.

2. Don’t reinvent the wheel (or the sensor)

A therapy-delivery wearable doesn’t have to own every biosignal. The strategic question for a new device startup is how to invest in signal acquisition in a manner that accelerates time-to-market without incurring unnecessary risk.

Look for proven reusable biosignal solutions. The underlying biosignal acquisition stack rarely needs to be invented from scratch. Reference designs, validated biosensors, and proven low-power signal processing can be leveraged and reused for most solutions. Capital spent rebuilding what’s already been de-risked is capital not spent on your proprietary algorithm and therapy mechanism.

Integrate signals from existing devices if they meet your bar. Pairing proprietary signals with data from a popular consumer or medical wearable can extend the system’s reach without expanding its scope. A consumer ring might supply recovery and autonomic context while the therapy device captures muscle activation near the treatment site. A smartwatch might contribute movement trends while the therapeutic wearable captures the local signals needed to titrate therapy. These external signals are only useful if they meet the accuracy and reliability requirements of your therapy. A consumer-grade reading that’s fine for fitness tracking may not be fine for a closed-loop intervention. Validating that bar before integrating is design work, not post-hoc QA.

The same discipline applies across all device layers. The competitive advantage in a wearable therapy company is in the clinical insight, the unique algorithm, the therapy mechanism, and the evidence package — not in reinventing system architecture, embedded firmware, power management, or verification strategy that has already been proven a hundred times over. Capital spent re-building those layers is capital not spent on the parts of the system that actually create defensibility.

Learn more here: From biosignals to clinical insights – how to derisk and accelerate your path to market

3. Apply the proper level of design controls at each stage

Formal design controls, documentation, and traceability are non-negotiable for any medical device. But they aren’t always the right place to start.

Sinking time and capital into exhaustive specifications before anything has been validated is a common way to miss the next milestone.

The discipline is sequencing: lean and fast in early feasibility, then scaling compliance rigor as the device matures and the questions sharpen. A lighter-weight approach early on tends to look like this:

• Capture user needs, key hazards, and product requirements informally.
• Build quick prototypes that test the riskiest assumptions first.
• Validate the therapy mechanism and signal logic before formalizing every requirement.

The closer the program gets to verification, validation, and submission, the more those structures have to be in place.

Learn more here: How to build your device faster while staying compliant using smart design controls

4. Treat power as a strategy issue, not just an engineering constraint

For therapy-delivery wearables, battery life and power management matter more than they do for monitoring devices. A therapy device that runs out of power is an interrupted treatment.

Power constraints shape what can be sensed, processed, stored, transmitted, analyzed, and delivered as therapy. They also shape the user experience, adherence, safety architecture, and commercial viability of the product.

There are many tradeoffs to consider, including:

• Always-on sensing isn’t always clinically necessary or technically optimal.
• Always-on therapy isn’t always safe, useful, or power-efficient.
• Edge processing reduces data transfer but increases local compute demand.
• Cloud processing enables richer analytics but introduces connectivity, latency, cybersecurity, privacy, and cost considerations.
• Therapy delivery itself draws power, and that draw has to be balanced against sensing, connectivity, and patient usability.
• Battery life can ultimately determine whether the device is worn consistently enough to generate meaningful therapeutic benefit and evidence, and an overly demanding charging schedule can reduce patient compliance.

These engineering decisions have significant strategic implications. The right time to make them is early, while they’re still architectural choices, and before they become expensive redesign problems.

Learn more : Balancing signal data vs. power consumption in your implantable device

5. Turn variable development cost into fixed-cost deliverables

In a market where funding takes longer and comes with greater security, capital efficiency and burn-rate predictability provide a hedge against running out of cash before the next funding round is secured.

Two operating strategies can help mitigate the risk. The first is conservative hiring paired with strategic outsourcing. Early hiring should focus on proprietary expertise and disciplines specific to the core IP of the company. Everything else — biosignal acquisition, low-power design, embedded firmware, regulatory strategy, manufacturing engineering — is a candidate for a specialized partner. That keeps cash burn predictable, preserves the option to adjust the in-house/outsourced mix as the program matures, and avoids the risk of having to downsize later.

The second is structuring engagements around fixed milestones rather than open-ended hourly projects. Fixed-cost, milestone-based work makes the cost of out-of-scope feature requests visible the moment they’re proposed, which makes scope discipline easier. It also aligns incentives: the partner succeeds when the milestone is reached, not when the clock runs longer.

The net effect in both cases is the same — turning what would otherwise be variable, unbounded spend into a predictable cost tied to a specific proof point. That’s what preserves runway between rounds.

Learn more : Lessons learned from a decade of milestone-based fixed cost projects

The takeaways

The next wearable opportunity is centered on therapy, not general-purpose sensing and monitoring. Neuromodulation and other targeted therapies represent a category that consumer wearables can’t follow into.

For founders building toward that opportunity, the practical implications cluster into a few clear ideas:

• Lead with the therapy hypothesis: The first proof point isn’t a finished platform — it’s evidence that the intervention works.
• Build the loop, not just the sensor: The defensible asset is the closed loop between therapy delivered and patient response captured.
• Invest in what’s defensible, leverage what isn’t: Generic context signals are commodity; unique therapy-site signals are moat.
• Make every dollar buy risk reduction: Sequence your priorities around proof-point milestones, apply design controls just in time, treat power as a strategy decision, and keep spend predictable between rounds.

The shift from monitoring to therapy changes what gets built, what gets measured, and what gets funded. The companies that internalize it early are the ones most likely to come ahead in the next wave of the wearable revolution.

See how we can help.